Philippa Newell

TL;DR: This review highlights the antitumor activity of sorafenib across a variety of tumor types, including renal cell, hepatocellular, breast, and colorectal carcinomas in the preclinical setting.

TL;DR: Three robust HCC subclasses are observed, each correlated with clinical parameters such as tumor size, extent of cellular differentiation, and serum alpha-fetoprotein levels, and it is indicated that S1 reflected aberrant activation of the WNT signaling pathway, S2 was characterized by proliferation as well as MYC and AKT activation, and S3 was associated with hepatocyte differentiation.

TL;DR: Overexpression of VEGFA via 6p21 gain in hepatocellular carcinomas suggested a novel, non-cell-autonomous mechanism of oncogene activation, and the prevalence of V EGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic therapies.

TL;DR: A review summarizes the most relevant information regarding structural and functional alterations in HCC and describes some of the key signaling pathways implicated in hepatocarcinogenesis.

TL;DR: A composite prognostic model for HCC recurrence is developed, based on gene expression patterns in tumor and adjacent tissues, which predict early and overall recurrence in patients with HCC, and complement findings from clinical and pathology analyses.